16 Results for "

LYTAC

" in MedChemExpress (MCE) Product Catalog:
Products (16)

16 Results for "LYTAC" in MCE Product Catalog:

Cat. No.: HY-148476
CAS No.: 2999748-27-3
Purity:  98.05%
Target:  

LYTACs

Research Areas:  

Metabolic Disease

Tri-GalNAc-DBCO is a synthetic ligand composed of three GalNAc units connected to DBCO. Tri-GalNAc-DBCO can act as a ligand for the sialic acid-degrading protein receptor (ASGPR), and can be coupled with targeting proteins or small molecules to form GalNAc-LYTACs. Tri-GalNAc-DBCO specifically binds to ASGPR and, through receptor-mediated endocytosis, guides the coupled molecules to lysosomes for degradation .
loading...
    loading...
Cat. No.: HY-148118A
CAS No.: 1159408-65-7
Purity:  98.09%
Target:  

LYTACs

Research Areas:  

Cancer

Tri-GalNAc(OAc)3 TFA is a trivalent N-acetylgalactosamine (GalNAc) derivative that can be used to synthesize GalNAc-LYTAC. Tri-GalNAc is a specific ligand targeting the asialoglycoprotein receptor (ASGPR), mediating the endocytosis and transport of cell surface proteins (such as EGFR, HER2) to lysosomes for degradation by lysosomal targeting chimeras (LYTACs). Tri-GalNAc significantly reduces the level of target proteins and inhibits downstream signaling pathways (such as EGFR-mediated Akt and MAPK signals). Tri-GalNAc(OAc)3 TFA can be used for hepatocyte targeting studies, and can degrade carcinogenic membrane proteins and inhibit tumor cell proliferation in liver cancer cell models .
loading...
    loading...
Cat. No.: HY-148118
CAS No.: 1159408-64-6
Purity:  98.09%
Target:  

LYTACs

Research Areas:  

Cancer

Tri-GalNAc(OAc)3 is a trivalent N-acetylgalactosamine (tri-GalNAc) derivative, which can be used as a linker to synthesize LYTACs .
loading...
    loading...
Cat. No.: HY-139482
CAS No.: 1953146-81-0
Purity:  98.43%
Target:  

LYTACs

Research Areas:  

Cancer

tri-GalNAc-COOH is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research .
loading...
    loading...
Cat. No.: HY-147354
CAS No.: 186613-57-0
Purity:  99.02%
Target:  

LYTACs

Research Areas:  

Cardiovascular Disease

TriGalNAc CBz is a GalNAc derivative and tri-GalNAc is an asialoglycoprotein receptor (ASGPR) ligand. TriGalNAc CBz can be used for mRNA drug delivery as well as lysosomal targeted chimerism (LYTAC) studies .
loading...
    loading...
Cat. No.: HY-147102
CAS No.: 3062597-46-7
Purity:  99.40%
Target:  

LYTACs

Research Areas:  

Metabolic Disease

tri-GalNAc biotin is a biotinylated ASGPR (Asialoglycoprotein receptor) ligand. tri-GalNAc biotin promotes cellular uptake of neutravidin (NA) via ASGPR. tri-GalNAc biotin delivers neutravidin to lysosomes for degradation. tri-GalNAc biotin can be used for research of LYsosome TArgeting Chimera (LYTAC) .
loading...
    loading...
Cat. No.: HY-145368B
Purity:  ≥95.0%
Target:  

LYTACs

Research Areas:  

Metabolic Disease

Tri-GalNAc(OAc)3-Perfluorophenyl is a pentafluorophenyl modified Tri-GalNAc(OAc)3 (HY-148118), a tri-GalNAc ligand that can be used for the synthesis of GalNAc-LYTAC. GalNAc-LYTAC engages the asialoglycoprotein receptor for targeted protein degradation.Tri-GalNAc(OAc)3-Perfluorophenyl can be used for the study of liver metabolism .
loading...
    loading...
Cat. No.: HY-171910
CAS No.: 3099288-71-5
Research Areas:  

Others

tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12) is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research .
loading...
    loading...
Cat. No.: HY-145013
CAS No.: 3008204-26-7
Target:  

LYTACs

Research Areas:  

Others

tri-GalNAc-COOH acetylation is the acetylated and modified form of tri-GalNAc-COOH. tri-GalNAc-COOH acetylation can be used for the synthesis of LYTAC.
loading...
    loading...
Cat. No.: HY-174476
CAS No.: 1472616-48-0
Target:  

HSP Drug Intermediate

Research Areas:  

Cancer

HSP90i is a HSP90 inhibitor. HSP90i can be used as a drug intermediate to synthesize LYTACs, such as dPDL1-4 (HY-174468) .
loading...
    loading...
Cat. No.: HY-174799
Target:  

HSP

Research Areas:  

Cancer

HSP90i-COCH2CH2-PEG4-NHBoc is a conjugate of the HSP90 Ligand (HY-174476) and the linker (HY-W021787). HSP90i-COCH2CH2-PEG4-NHBoc can be used for synthesis of LYTACs, such as dPDL1-4 (HY-174468) .
loading...
    loading...
Cat. No.: HY-164396
CAS No.: 3030990-46-3
Target:  

Drug Derivative LYTACs

Research Areas:  

Cancer

Allyl-mannose-6-phosphonate is a stable analog of mannose-6-phosphate (M6P). Allyl-mannose-6-phosphonate can be used to synthesize M6Pn-polypeptide conjugates and construct lysosome-targeting chimeras (LYTAC). Allyl-mannose-6-phosphonate is applicable for tumor research .
loading...
    loading...
Cat. No.: HY-184774
CAS No.: 1551528-06-3
Target:  

Drug Intermediate

Research Areas:  

Others

tri-GalNAc-C10-COOH (P290 232) is a targeted delivery intermediate composed of a trivalent N-acetylgalactosamine (GalNAc) cluster attached to a C10 linker ending with a carboxylic acid (-COOH) group. tri-GalNAc-C10-COOH is a standard building block used to synthesize LYTACs (lysosome-targeting chimeras) and cell-specific oligonucleotides like siRNA or ASO therapeutics .
loading...
    loading...
Cat. No.: HY-181830
Target:  

PD-1/PD-L1 PSMA LYTACs

Research Areas:  

Cancer

Atz-L5 is a PD-L1 PTAC (PSMA-targeted chimera) degrader (DC50: 18 pM in PC3-PIP cells; 2 pM in LNCaP cells) and LYTAC. Atz-L5 promotes lysosomal degradation of PD-L1 in PSMA-positive prostate cancer cells. Atz-L5 is applicable to the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-181829
Target:  

EGFR PSMA LYTACs

Research Areas:  

Cancer

Ctx-L3 is a selective EGFR PTAC (PSMA-targeted chimera) degrader (DC50: 4.3 pM in LNCaP cells) and LYTAC. Ctx-L3 recruits prostate-specific membrane antigen (PSMA) and mediates lysosomal degradation of EGFR in PSMA-positive prostate cancer cells. Ctx-L3 exhibits degrading activity against EGFR in prostate cancer cells. Ctx-L3 is applicable to related research on prostate cancer .
loading...
    loading...
Cat. No.: HY-184926
PEG9MA10-PAB10-GalMA10 is a CD147 LYTAC degrader. PEG9MA10-PAB10-GalMA10 binds to the asialoglycoprotein receptor (ASGPR) via its galactose methacrylate domain, mediating its uptake by hepatoma cells. PEG9MA10-PAB10-GalMA10 induces lysosome-dependent degradation of CD147, resulting in concurrent loss of associated MCT1 and MCT4. PEG9MA10-PAB10-GalMA10 reduces extracellular lactate levels, increases intracellular lactate accumulation, inhibits glycolytic activity, and enhances mitochondrial respiratory capacity. PEG9MA10-PAB10-GalMA10 decreases the secretion of MMP-2 and MMP-9, and upregulates the expression of E-cadherin. PEG9MA10-PAB10-GalMA10 exhibits anti-tumor efficacy in hepatoma models. PEG9MA10-PAB10-GalMA10 can be used for research on liver cancer (hepatocellular carcinoma) .
loading...
    loading...
  • 1